Literature DB >> 7093115

Duration of effect of single daily dose methyldopa therapy.

J M Wright, M Orozco-Gonzalez, G Polak, C T Dollery.   

Abstract

1 Methyldopa has a short plasma half-life, but longer duration of antihypertensive effect. A single bedtime dose of methyldopa has been recommended to improve compliance and decrease side effects. 2 This double-blind crossover study was designed to determine the duration of antihypertensive effect of methyldopa by comparing hourly supine and standing blood pressures, throughout the day during placebo, single morning dose, and single evening dose methyldopa therapy in 10 patients. The major side effects, drowsiness and dry mouth were assessed by visual analogue scale. Exercise blood pressures were measured 6, 12, 18 and 24 h after the dose. 3 The antihypertensive effect of methyldopa peaked after 6-9 h and declined thereafter with a half-life of approximately 10 h. Little antihypertensive effect remained 24-26 h after the dose. The time course of the reduction in blood pressure during exercise and of the major side effects paralleled the antihypertensive effects. 4 The results suggest that the duration of antihypertensive effect of methyldopa is long enough to permit twice daily dosing, but that single daily dosing cannot be recommended for most patients. The study illustrates the importance of knowing the time of the last methyldopa dose when assessing blood pressure measurements in patients taking the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093115      PMCID: PMC1402027          DOI: 10.1111/j.1365-2125.1982.tb01877.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Methyldopa in hypertension. Clinical and pharmacological studies.

Authors:  C T DOLLERY; M HARINGTON
Journal:  Lancet       Date:  1962-04-14       Impact factor: 79.321

2.  Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

Authors:  L GILLESPIE; J A OATES; J R CROUT; A SJOERDSMA
Journal:  Circulation       Date:  1962-02       Impact factor: 29.690

3.  Pharmacokinetics of methyldopa in healthy man.

Authors:  O Stenbaek; E Myhre; H E Rugstad; E Arnold; T Hansen
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

4.  Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions.

Authors:  R B Haynes; D L Sackett; D W Taylor; R S Roberts; A L Johnson
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

5.  Twice daily methyldopa: home blood pressure recordings.

Authors:  L Wilson; A Roberts; M O'Halloran
Journal:  Med J Aust       Date:  1979-10-06       Impact factor: 7.738

6.  Laboratory note. Effects of methyldopa on sleep patterns in man.

Authors:  F Baekeland; L Lundwall
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1971-09

7.  Pharmacokinetics of methyldopa in man.

Authors:  K C Kwan; E L Foltz; G O Breault; J E Baer; J A Totaro
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

8.  Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

Authors:  J A OATES; L GILLESPIE; S UDENFRIEND; A SJOERDSMA
Journal:  Science       Date:  1960-06-24       Impact factor: 47.728

9.  Antihypertensive efficacy of a single bedtime dose of methyldopa.

Authors:  J M Wright; P J McLeod; W McCullough
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

10.  Circadian variation of blood-pressure.

Authors:  M W Millar-Craig; C N Bishop; E B Raftery
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

  10 in total
  4 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Lithium-methyldopa interaction.

Authors:  R Yassa
Journal:  CMAJ       Date:  1986-01-15       Impact factor: 8.262

Review 3.  Methyldopa for primary hypertension.

Authors:  Greg T Mah; Aaron M Tejani; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 4.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.